Aspirin desensitization for aspirin‐exacerbated respiratory disease in the era of biologics: Clinical perspective.

The postoperative state allows for topical steroid therapy, ATAD, and other established therapies to be more effective for the majority of cases at a fraction of the cost of a T2 biologic. Forty years ago, researchers at the Scripps Clinic desensitized 2 aspirin-exacerbated respiratory disease (AERD) patients to aspirin and noticed that the rate of regrowth of their polyps had abated with continued aspirin therapy. There will remain a minority of patients who are either intolerant to aspirin, have an aspirin contraindication, have a surgical contraindication, refuse surgery or aspirin desensitization, or do not have an excellent response to these coordinated therapies. [Extracted from the article]